IGF2BP1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma cell line. This product provides a mixed population of cells with targeted disruption of the IGF2BP1 gene, enabling loss-of-function studies in an immortalized cancer model. The polyclonal format captures a diverse array of editing events without selection for single-cell clones, offering a robust and cost-effective platform for investigating the functional consequences of IGF2BP1 depletion.
The parental HeLa line originates from a cervical adenocarcinoma and is one of the most extensively utilized cell models in biomedical research. As an immortalized epithelial cell line, HeLa cells exhibit robust proliferative capacity and are permissive to a wide range of genetic manipulations. They serve as a foundational system for studying cancer biology, including signaling transduction, cell cycle regulation, and metastatic processes, and are particularly valued for their ease of culture and experimental tractability.
IGF2BP1 encodes an RNA-binding protein that primarily stabilizes target mRNAs by binding to their 3′ untranslated regions, facilitating recruitment to polysomes for active translation. It functions downstream of key oncogenic signals including MYC, KRAS, and growth factor pathways such as EGF and insulin-like growth factors, and participates in Wnt/???catenin and TGF???/SMAD cascades. IGF2BP1 physically interacts with poly(A)-binding protein (PABP), eukaryotic initiation factors, and ribosomal subunits, and shares functional overlap with family members IGF2BP2 and IGF2BP3. Its recognized downstream targets include MYC, KRAS, CD44, ACTB, and PTEN mRNAs, directly linking IGF2BP1 to regulation of proliferation, adhesion, and survival.
In the HeLa context, disruption of IGF2BP1 is expected to destabilize oncogenic transcripts normally stabilized by this protein, leading to reduced synthesis of proteins such as MYC and CD44 that drive proliferation and migration. Consequently, the knockout population can display impaired cell growth, diminished colony formation, and attenuated migratory capacity, mirroring the oncofetal role of IGF2BP1 in malignancies. This model enables dissection of post-transcriptional regulatory networks that are aberrantly activated during cervical carcinogenesis and in cancers where IGF2BP1 overexpression is frequently observed, such as colorectal, lung, and breast cancers.
Applications include probing mRNA stability and translation control via RT?qPCR monitoring of target transcript levels, actinomycin D chase assays, and RNA immunoprecipitation to validate direct binding interactions. The polyclonal knockout cells are suited for transwell migration and MTT?based proliferation assays to quantify functional deficits, as well as western blotting to assess changes in MYC, ???catenin, or SMAD2/3 protein levels. Further uses involve identifying IGF2BP1?dependent transcripts through transcriptomic profiling, validating chemical probes or siRNAs targeting the IGF2BP family, and exploring compensatory mechanisms involving IGF2BP2 or IGF2BP3. For technical inquiries or to discuss custom applications, please contact Ascent Research.
